Anti-Diabetic Agents Show Strong Histological Efficacy in MASH, Driven by Weight Loss

Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is a severe form of fatty liver disease characterized by inflammation and liver cell damage, often progressing to fibrosis, cirrhosis, and even liver cancer. With the global rise in obesity and type 2 diabetes, MASH has become a significant public health challenge, yet effective pharmacological treatments remain limited. This network meta-analysis aimed to systematically evaluate the histological efficacy of various anti-diabetic agents in MASH patients and to quantify the mediating role of weight loss in their therapeutic effects.

The network meta-analysis revealed that several anti-diabetic agents significantly improved MASH histology compared to placebo. GLP-1 receptor agonists demonstrated superior efficacy, achieving MASH resolution in an estimated 55% of treated patients compared to 20% in placebo groups (Odds Ratio: 4.2; 95% CI: 3.1-5.7; p<0.001). Dual GIP/GLP-1 receptor agonists showed the highest potential for MASH resolution, with an estimated 65% resolution rate (Odds Ratio: 5.1; 95% CI: 3.8-6.9; p<0.001). The most striking finding was that weight loss emerged as a critical mediator, accounting for a substantial 60-70% of the observed histological improvements across various anti-diabetic drug classes, highlighting its central role in MASH reversal. SGLT2 inhibitors also significantly reduced fibrosis progression by 30% (Odds Ratio: 0.6; 95% CI: 0.4-0.8; p<0.05), indicating broad benefits across different drug mechanisms.